Similarly, Crossland et al. [111] demonstrated CD56 directed CAR-T cells in neuroblastoma and SCLC mouse models with significant reduction in tumor burden after infusion, and a modest effect on OS, though safety concerns remain due to the potential for on-target, off tissue toxicity, particularly given CD56’s expression in neural cells. This evidence concerns the gene NCAM1 and neoplasm.